-
Signature
-
/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook
-
Issuer symbol
-
ANIP
-
Transactions as of
-
20 Feb 2026
-
Net transactions value
-
-$415,300
-
Form type
-
4
-
Filing time
-
23 Feb 2026, 17:31:50 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Mutz Christopher |
HEAD OF RARE DISEASE |
C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE |
/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook |
23 Feb 2026 |
0001846487 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ANIP |
Common Stock |
Sale |
$415,300 |
-5,323 |
-5.9% |
$78.02 |
84,840 |
20 Feb 2026 |
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: